Article
Radiology, Nuclear Medicine & Medical Imaging
Dominique Clement, Shaunak Navalkissoor, Rajaventhan Srirajaskanthan, Frederic Courbon, Lawrence Dierickx, Amy Eccles, Valerie Lewington, Mercedes Mitjavila, Juan Carlos Percovich, Benoit Lequoy, Beilei He, Ilya Folitar, John Ramage
Summary: The study found that Lu-177-DOTATATE is effective and safe for the treatment of patients with advanced pancreatic neuroendocrine tumors (panNETs).
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Oncology
Alexandra Leary, Ana Oaknin, Jose Manuel Trigo, Victor Moreno, Jean-Pierre Delord, Valentina Boni, Irene Brana, Cristian Fernandez, Carmen Kahatt, Antonio Nieto, Martin Cullell-Young, Ali Zeaiter, Vivek Subbiah
Summary: Lurbinectedin is an approved drug for the treatment of metastatic small cell lung cancer. This study analyzes safety data from various solid tumors treated with Lurbinectedin, and confirms its manageable safety profile in patients with advanced solid tumors.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Vikas Gupta, Martin Griesshammer, Bruno Martino, Lynda Foltz, Renato Tavares, Haifa Kathrin Al-Ali, Pilar Giraldo, Paola Guglielmelli, Elza Lomaia, Catherine Bouard, Carole Paley, Ranjan Tiwari, Evren Zor, Pia Raanani
Summary: The large JUMP study analyzed factors predictive of spleen and symptom responses in myelofibrosis patients receiving ruxolitinib. Results showed that lower IPSS risk, earlier treatment initiation, and higher ruxolitinib doses were associated with increased spleen response rates, but not symptom improvement.
LEUKEMIA & LYMPHOMA
(2021)
Article
Oncology
Paolo A. Ascierto, Anna M. Di Giacomo, Vanna Chiarion Sileni, Paola Queirolo, Francesco Spagnolo, Federica De Galitiis, Francesco Cognetti, Mario Mandala, Massimo Guidoboni, Gaetana Rinaldi, Roberta Depenni, Francesca Consoli, Teresa Troiani, Michele Guida, Riccardo Marconcini, Pier F. Ferrucci, Sabino Strippoli, Paolo Fava, Barbara Merelli, Ester Simeone, Lorenza Di Guardo, Diana Giannarelli, Massimo Maio, Pietro Quaglino, Michele Del Vecchio
Summary: The CheckMate 238 study demonstrated the benefits of nivolumab over ipilimumab for melanoma patients and showed a tolerable safety profile. The Italian Expanded Access Programme enrolled 611 patients with resected melanoma and showed similar clinical activity and safety of nivolumab in a real-life setting.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
T. Cascone, R. L. Sacks, I. M. Subbiah, N. Drobnitzky, S. A. Piha-Paul, D. S. Hong, K. R. Hess, B. Amini, T. Bhatt, S. Fu, A. Naing, F. Janku, D. Karp, G. S. Falchook, A. P. Conley, S. Sherman, F. Meric-Bernstam, A. J. Ryan, J. Heymach, V Subbiah
Summary: The combination therapy of VAN + EV shows promising antitumor activity in advanced solid cancers, with manageable toxicities. Further studies are needed to explore its efficacy in tumors with RET pathway aberrations.
Article
Oncology
Paolo Antonio Ascierto, Kristina Orlova, Giovanni Grignani, Monika Dudzisz-Sledz, Eyal Fenig, Vanna Chiarion Sileni, Nicola Fazio, Mahtab Samimi, Laurent Mortier, Christoffer Gebhardt, Nora Kramkimel, Neil Steven, Oliver Bechter, Ana Arance, Elena Benincasa, Lenka Kostkova, Nuno Costa, Paul Lorigan
Summary: Avelumab has been proven to be effective and safe as a treatment option for patients with metastatic Merkel cell carcinoma in Europe and the Middle East. The majority of patients received avelumab as second-line treatment, with a high objective response rate observed.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Toni Choueiri, Camillo Porta, Cristina Suarez, John Hainsworth, Eric Voog, Ignacio Duran, James Reeves, Piotr Czaykowski, Daniel Castellano, Jingjing Chen, Farhad Sedarati, Thomas Powles
Summary: This study evaluated the efficacy and safety of single-agent sapanisertib and sapanisertib plus the PI3K alpha inhibitor TAK-117 versus everolimus in patients with advanced clear cell renal cell carcinoma that had progressed on or after VEGF-targeted therapy. The results showed that sapanisertib, with or without TAK-117, was not more effective than everolimus in improving outcomes in patients with relapsed or refractory advanced ccRCC, and had lower tolerability.
Article
Pharmacology & Pharmacy
Masaki Hirabatake, Tomoyuki Mizuno, Hironori Kato, Tohru Hashida
Summary: This study aimed to characterize the pharmacokinetics of everolimus and investigate its relationship with efficacy and adverse events in patients with breast cancer. The results showed that high exposure to everolimus was associated with poor tolerability, while plasma concentrations in the range of 10-20 ng/ml may be associated with prolonged progression-free survival.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Scott S. Tykodi, Lucio N. Gordan, Robert S. Alter, Edward Arrowsmith, Michael R. Harrison, Ivor Percent, Rakesh Singal, Peter Van Veldhuizen, Daniel J. George, Thomas Hutson, Joshua Zhang, Jesus Zoco, Jennifer L. Johansen, Arash Rezazadeh Kalebasty
Summary: The study evaluated the safety and efficacy of nivolumab plus ipilimumab in previously untreated advanced non-clear cell renal cell carcinoma (nccRCC) patients, showing a partial response rate of 19.6%, a median progression-free survival of 3.7 months, and a median overall survival of 21.2 months.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Medicine, General & Internal
Jonathon W. Senefeld, Patrick W. Johnson, Katie L. Kunze, Evan M. Bloch, Noud van Helmond, Michael A. Golafshar, Stephen A. Klassen, Allan M. Klompas, Matthew A. Sexton, Juan C. Diaz Soto, Brenda J. Grossman, Aaron A. R. Tobian, Ruchika Goel, Chad C. Wiggins, Katelyn A. Bruno, Camille M. van Buskirk, James R. Stubbs, Jeffrey L. Winters, Arturo Casadevall, Nigel S. Paneth, Beth H. Shaz, Molly M. Petersen, Bruce S. Sachais, Matthew R. Buras, Mikolaj A. Wieczorek, Benjamin Russoniello, Larry J. Dumont, Sarah E. Baker, Ralph R. Vassallo, John R. A. Shepherd, Pampee P. Young, Nicole C. Verdun, Peter Marks, N. Rebecca Haley, Robert F. Rea, Louis Katz, Vitaly Herasevich, Dan A. Waxman, Emily R. Whelan, Aviv Bergman, Andrew J. Clayburn, Mary Kathryn Grabowski, Kathryn F. Larson, Juan G. Ripoll, Kylie J. Andersen, Matthew N. P. Vogt, Joshua J. Dennis, Riley J. Regimbal, Philippe R. Bauer, Janis E. Blair, Zachary A. Buchholtz, Michaela C. Pletsch, Katherine Wright, Joel T. Greenshields, Michael J. Joyner, R. Scott Wright, Rickey E. Carter, DeLisa Fairweather
Summary: This study provides insight into the demographic, geographical, and chronological characteristics of patients in the US Expanded Access Program for COVID-19 convalescent plasma, as well as key safety metrics following plasma transfusion. The majority of patients were male and over 60 years old with a high prevalence of overweight or obesity, and there was significant inclusion of minorities and underserved populations. The EAP was able to provide widespread access to convalescent plasma across all 50 states with low incidence of serious adverse events.
Article
Oncology
Francesco Passamonti, Vikas Gupta, Bruno Martino, Lynda Foltz, Andrey Zaritskey, Haifa Kathrin Al-Ali, Renato Tavares, Margherita Maffioli, Pia Raanani, Pilar Giraldo, Martin Griesshammer, Paola Guglielmelli, Catherine Bouard, Carole Paley, Ranjan Tiwari, Alessandro M. Vannucchi
Summary: The study demonstrates that ruxolitinib is safe and effective for patients with myelofibrosis across different risk categories, with lower-risk patients showing more significant benefits.
HEMATOLOGICAL ONCOLOGY
(2021)
Article
Oncology
Suzanne L. Topalian, Mario Sznol, David F. McDermott, Harriet M. Kluger, Richard D. Carvajal, William H. Sharfman, Julie R. Brahmer, Donald P. Lawrence, Michael B. Atkins, John D. Powderly, Philip D. Leming, Evan J. Lipson, Igor Puzanov, David C. Smith, Janis M. Taube, Jon M. Wigginton, Georgia D. Kollia, Ashok Gupta, Drew M. Pardoll, Jeffrey A. Sosman, F. Stephen Hodi
Summary: PD-1 blockade therapy can effectively reduce tumors and improve survival rates in patients with advanced melanoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Arsela Prelaj, Achille Bottiglieri, Claudia Proto, Giuseppe Lo Russo, Diego Signorelli, Roberto Ferrara, Giulia Galli, Alessandro De Toma, Giuseppe Viscardi, Marta Brambilla, Riccardo Lobefaro, Federico Nichetti, Sara Manglaviti, Mario Occhipinti, Alice Labianca, Monica Ganzinelli, Rosaria Gallucci, Nicoletta Zilembo, Gabriella Francesca Greco, Valter Torri, Filippo de Braud, Marina C. Garassino
Summary: This study investigated the use of Poziotinib in patients with EGFR/HER2 exon 20 insertion mutation metastatic non-small-cell lung cancer, showing a median progression-free survival of 5.6 months and a median overall survival of 9.5 months. The overall response rate was 30% and the disease control rate was 80%. Main toxicities included skin rash and diarrhea.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Clinical Neurology
Jerzy P. P. Szaflarski, Orrin Devinsky, Merrick Lopez, Yong D. D. Park, Pilar Pichon Zentil, Anup D. D. Patel, Elizabeth A. A. Thiele, Robert T. T. Wechsler, Daniel Checketts, Farhad Sahebkar
Summary: The CBD expanded access program initiated in 2014 provided additional CBD treatment for patients with treatment-resistant epilepsies. The study showed that CBD treatment was effective in reducing seizure frequency and had an acceptable safety profile for long-term use in patients with treatment-resistant epilepsies.
Article
Oncology
Capucine Baldini, Francois-Xavier Danlos, Andreea Varga, Matthieu Texier, Heloise Halse, Severine Mouraud, Lydie Cassard, Stephane Champiat, Nicolas Signolle, Perrine Vuagnat, Patricia Martin-Romano, Jean-Marie Michot, Rastislav Bahleda, Anas Gazzah, Lisa Boselli, Delphine Bredel, Jonathan Grivel, Chifaou Mohamed-Djalim, Guillaume Escriou, Laetitia Grynszpan, Amelie Bigorgne, Saloomeh Rafie, Alae Abbassi, Vincent Ribrag, Sophie Postel-Vinay, Antoine Hollebecque, Sandrine Susini, Siham Farhane, Ludovic Lacroix, Aurelien Parpaleix, Salim Laghouati, Laurence Zitvogel, Julien Adam, Nathalie Chaput, Jean-Charles Soria, Christophe Massard, Aurelien Marabelle
Summary: This study investigated the safety and efficacy of the combination therapy of nintedanib and pembrolizumab in patients with advanced solid tumors. The recommended dose for combination therapy was determined to be 150 mg twice daily of nintedanib. Early tumor and circulating immune factors were found to be associated with cancer outcome under this combination therapy.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Medicine, General & Internal
Veerle Casneuf, Ivan Borbath, Marc van den Eynde, Yolanda Verheezen, Wim Demey, Alain G. Verstraete, Kathleen Bm Claes, Vincent Haufroid, Karen P. Geboes
Summary: Fluoropyrimidines are commonly used in the treatment of malignancies, but genetic variations within the DPYD gene can lead to reduced DPD activity, causing potential toxicity. In Belgium, screening for DPD deficiency before starting treatment with fluoropyrimidines is recommended, with a preference for phenotype testing due to higher sensitivity and lower cost to society.
ACTA CLINICA BELGICA
(2022)
Article
Oncology
Laura Gadeyne, Yannick Van Herck, Giorgia Milli, Zeynep Kalender Atak, Maddalena Maria Bolognesi, Jasper Wouters, Lukas Marcelis, Angeliki Minia, Vaia Pliaka, Jan Roznac, Leonidas G. Alexopoulos, Giorgio Cattoretti, Oliver Bechter, Joost Van Den Oord, Frederik De Smet, Asier Antoranz, Francesca Maria Bosisio
Summary: The study revealed that HLA-DR positive areas in melanoma attract anti-tumor immune cell infiltration by creating a dystrophic germinal center-like microenvironment where enhanced antigen presentation lead to exhausted immune environment. This could actually represent a fertile ground for better efficacy of anti-PD-1 inhibitors due to simultaneous higher levels of PD-1 in immune cells and PD-L1 in HLA-DR positive melanoma cells.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Ali Belkouz, Stijn Van Roessel, Marin Strijker, Jacob L. van Dam, Lois Daamen, Lydia G. van der Geest, Alberto Balduzzi, Andrea Benedetti Cacciaguerra, Susan van Dieren, Quintus Molenaar, Bas Groot Koerkamp, Joanne Verheij, Elizabeth Van Eycken, Giuseppe Malleo, Mohammed Abu Hilal, Martijn G. H. van Oijen, Ivan Borbath, Chris Verslype, Cornelis J. A. Punt, Marc G. Besselink, Heinz-Josef Klumpen
Summary: This study developed and validated a prediction model for 3-year overall survival (OS) after pancreatoduodenectomy for distal cholangiocarcinoma (dCCA). Through the use of prognostic factors such as age, tumor stage, lymph node involvement, resection margin status, and tumor differentiation, patients were stratified into three risk groups with different prognoses. The model showed reasonable performance in both the derivation and external validation cohorts.
BRITISH JOURNAL OF CANCER
(2022)
Article
Gastroenterology & Hepatology
Pierre H. Deprez, Leon M. G. Moons, Dermot O'Toole, Rodica Gincul, Andrada Seicean, Pedro Pimentel-Nunes, Gloria Fernandez-Esparrach, Marcin Polkowski, Michael Vieth, Ivan Borbath, Tom G. Moreels, Els Nieveen van Dijkum, Jean-Yves Blay, Jeanin E. van Hooft
Summary: This article provides recommendations for the characterization and management of subepithelial lesions (SELs), including the use of endoscopic ultrasonography (EUS) for characterization, tissue diagnosis for SELs with features suggestive of gastrointestinal stromal tumor (GIST), and surveillance strategies for SELs based on size and diagnosis.
Article
Endocrinology & Metabolism
Ivan Borbath, Ulrich-Frank Pape, Pierre H. Deprez, Detlef Klaus Bartsch, Martyn Caplin, Massimo Falconi, Rocio Garcia-Carbonero, Simona Grozinsky-Glasberg, Robert T. Jensen, Rudolf Arnold, Philippe Ruszniewski, C. Toumpanakis, Juan W. Valle, Dermot O. Toole
Summary: Despite efforts to standardize reporting in the field of endoscopy, there is still a lack of consistency. The goal of standardized reporting is to improve diagnostic accuracy and effectiveness, optimize disease management, and reduce the burden on patients.
JOURNAL OF NEUROENDOCRINOLOGY
(2022)
Article
Medicine, General & Internal
Bruno Waked, Filip De Maeyer, Saskia Carton, Pieter-Jan Cuyle, Timon Vandamme, Chris Verslype, Pieter Demetter, Ivan Borbath, Liesbet Van Eycken, Anne Hoorens, Karen Geboes, Nancy Van Damme, Suzane Ribeiro
Summary: The incidence of rectal neuroendocrine neoplasms in Belgium has been increasing over the past decade, with improvements in pathology reporting quality seen after the WHO classification update in 2010. Most cases followed the recommended mode of treatment according to ENETS guidelines, but there is still room for improvement in reporting certain indicators like tumor size and lymphovascular invasion.
ACTA CLINICA BELGICA
(2022)
Review
Oncology
G. Roeyen, F. Berrevoet, I Borbath, K. Geboes, M. Peeters, B. Topal, E. Van Cutsem, J-L Van Laethem
Summary: Pancreatic exocrine insufficiency (PEI) is a common condition in patients with pancreatic cancer (PC). PERT treatment is widely used, but there is limited clinical evidence supporting its effectiveness. More research is needed to evaluate the efficacy of PERT in PC patients.
Article
Oncology
Gontran Verset, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Vittorina Zagonel, Per Stal, Debashis Sarker, Daniel H. Palmer, Arndt Vogel, Julien Edeline, Stephane Cattan, Masatoshi Kudo, Ann-Lii Cheng, Sadahisa Ogasawara, Bruno Daniele, Stephen L. Chan, Jennifer J. Knox, Shukui Qin, Abby B. Siegel, Michael Chisamore, Ken Hatogai, Anran Wang, Richard S. Finn, Andrew X. Zhu
Summary: This study aimed to evaluate the efficacy and tolerability of pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) who had not received prior systemic therapy. The results showed that pembrolizumab demonstrated durable antitumor activity and a favorable safety profile in this patient population, supporting further evaluation of pembrolizumab-based regimens for HCC treatment.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Ivan Borbath, Rocio Garcia-Carbonero, Damir Bikmukhametov, Paula Jimenez-Fonseca, Angel Castano, Jaroslava Barkmanova, Eva Sedlackova, Attila Kollar, Emanuel Christ, Gregory Kaltsas, Beata Kos-Kudla, Sebastian Maasberg, Chris Verslype, Ulrich-Frank Pape
Summary: This study analyzed data from the European Neuroendocrine Tumour Society registry, including 10,102 NEN patients from 7 European countries. It described prognostic factors for NEN survival in Europe, including primary tumor site, grade, stage, and treatment.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Philippe D'Abadie, Stephan Walrand, Michel Hesse, Ivan Borbath, Renaud Lhommel, Francois Jamar
Summary: This study evaluated the use of EUD-based Y-90 TOF-PET/CT in assessing metabolic response post-RE in HCC. The results showed a correlation between PET-based tumors EUD and clinical response, and a similar TCP curve to that observed in EBRT.
Article
Oncology
Come Lepage, Jean-Marc Phelip, Astrid Lievre, Karine Le-Malicot, Laetitia Dahan, David Tougeron, Christos Toumpanakis, Frederic Di-Fiore, Catherine Lombard-Bohas, Ivan Borbath, Romain Coriat, Thierry Lecomte, Rosine Guimbaud, Caroline Petorin, Jean-Louis Legoux, Pierre Michel, Jean-Yves Scoazec, Denis Smith, Thomas Walter
Summary: This study aimed to evaluate the efficacy of lanreotide autogel 120 mg as maintenance treatment for aggressive duodeno-pancreatic neuroendocrine tumors. The results showed that the lanreotide group had a progression-free survival (PFS) of 73.1% at 6 months, compared to 54.2% in the placebo group. The median PFS was 19.4 months in the lanreotide group and 7.6 months in the placebo group.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Endocrinology & Metabolism
Louis de Mestier, Matthieu Resche-Rigon, Clarisse Dromain, Angela Lamarca, Anna La Salvia, Lesley de Baker, Uli Fehrenbach, Sara Pusceddu, Annamaria Colao, Ivan Borbath, Robbert de Haas, Maria Rinzivillo, Alessandro Zerbi, Luigi Funicelli, Wouter W. de Herder, Andreas Selberherr, Anna Dorothea Wagner, Prakash Manoharan, Andrea De Cima, Willem Lybaert, Henning Jann, Natalie Prinzi, Antongiulio Faggiano, Laurence Annet, Annemiek Walenkamp, Francesco Panzuto, Vittorio Pedicini, Maria Giovanna Pitoni, Alexander Siebenhuener, Marius E. Mayerhoefer, Philippe Ruszniewski, Marie-Pierre Vullierme
Summary: In this study, alternative criteria for evaluating the efficacy of systemic treatments in patients with neuroendocrine tumors (NETs) and liver metastases (LMs) were explored. It was found that a reduction of ≥10% in the size of three LMs predicted prolonged treatment duration, which is more clinically relevant than the current threshold of 30% utilized by RECIST 1.1.
JOURNAL OF NEUROENDOCRINOLOGY
(2023)
Article
Rheumatology
George J. Greene, Jennifer L. Beaumont, Emily J. Bacalao, Azra Muftic, Karen Kaiser, Amy R. Eisenstein, Arthur M. Mandelin, David Cella, Eric M. Ruderman
Summary: This study evaluated the effect of a patient-centered "treat-to-target" (T2T) rheumatoid arthritis (RA) disease management approach on patient outcomes and satisfaction with care. The study found that integrating the PROMIS assessment system into RA treatment can improve disease activity and increase patient satisfaction.
JOURNAL OF RHEUMATOLOGY
(2023)
Letter
Gastroenterology & Hepatology
A. Dubail, C. Galant, I. Borbath, F. Lecouvet, A. Chaouki, O. Barbier, P. Baldin
ACTA GASTRO-ENTEROLOGICA BELGICA
(2022)
Review
Oncology
Philippe d'Abadie, Stephan Walrand, Renaud Lhommel, Michel Hesse, Ivan Borbath, Francois Jamar
Summary: Selective internal radiation therapy (SIRT) plays a crucial role in treating hepatocellular carcinoma (HCC), with dosimetry playing a key role in predicting patient outcomes. Personalized dosimetry planning can optimize the effectiveness of SIRT, while patient and tumor characteristics can also impact treatment outcomes.